Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from ImmuPharma ( (GB:IMM) ).
ImmuPharma has filed a new patent application for its lead asset P140, the world’s first ‘Immunormalizer,’ which offers a novel diagnostic test and precision treatment for autoimmune diseases. This patent provides the potential for 20 years of commercial exclusivity and positions ImmuPharma as a leader in precision medicine for autoimmune diseases. The new approach targets a subpopulation of patients with Type M immune disorder, offering a safer and more effective alternative to current treatments. The diagnostic test is expected to improve patient selection for clinical trials, enhance the probability of regulatory approval, and create significant commercial opportunities in the autoimmune diagnostics market.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics aimed at treating autoimmune diseases and anti-infectives.
Average Trading Volume: 2,184,678
Technical Sentiment Signal: Sell
Current Market Cap: £11.12M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.